Anti-CD30 antibody-based therapy

Current Opinion in Oncology

Volumn 12, Issue 6, 2000, Pages 588-593

  Koon, Henry B ^a   Junghans, Richard P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIBIOTIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; APOPTOSIS; CELL VIABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; GROWTH INHIBITION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIGENS, CD30; CLINICAL TRIALS; HUMANS; IMMUNOTOXINS; MODELS, BIOLOGICAL; NEOPLASMS; RADIOIMMUNOTHERAPY; RECEPTORS, IGG;

EID: 0034501637     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200011000-00012     Document Type: Review

References (44)

1. Structural and biological features of the TNF receptor and TNF ligand superfamilies: Interactive signals in the pathobiology of Hodgkin's disease
2. TNF-related ligands and their receptors
3. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders
4. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines
5. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts
6. Aging increases CD8 T cell apoptosis induced by hyperstimulation but decreases apoptosis induced by agonist withdrawal in mice
7. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
8. Lymphomatoid papulosis, Ki-1+ lymphoma, and primary cutaneous Hodgkin's disease
9. CD30 expression in normal and neoplastic lymphoid tissue: Biological aspects and clinical implications
10. Expression of CD30 and nerve growth factor-receptor in neoplastic and reactive vascular lesions: An immunohistochemical study
11. Expression of the CD30 antigen in non-lymphoid tissues and cells
12. CD30 expression is common in mediastinal large B-cell lymphoma
13. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule
14. Antibody-based immunotherapies for cancer
15. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells
16. Characterization of giant cells in Hodgkin's lymphomas by immunohistochemistry applied to randomly collected diagnostic biopsies from the German Hodgkin Trial
17. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies
18. A murine xenograft model for human CD30+ anaplastic large cell lymphoma: Successful growth inhibition with an anti-CD30 antibody (HeFi-1)
19. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence
20. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
21. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
22. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
23. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
24. Targeting of cytotoxic cells with hetero-crosslinked antibodies
25. A bispecific diabody that medicates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors
26. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies
27. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies
28. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo
29. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: Stimulation of cytotoxic pathways in vivo
30. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: The role of human T-cell subsets in a preclinical model
31. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease
32. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA′) is a potent immunotoxin against a Hodgkin-derived cell line
33. Anti-CD30 immunotoxins with native and recombinant dianthin 30
34. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma
35. Anti-CD30 (BER-H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice
36. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab fragments on solid human Hodgkin's disease tumors in mice
37. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease
38. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SClD mice using high-affinity monoclonal antibodies directed against the CD30 antigen
39. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
40. CD30L-ETA′: A new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma
41. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4)
42. Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation
43. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins
44. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin